Adamas Pharmaceuticals reported 115.66M in Current Assets for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Acadia Pharmaceuticals ACAD:US $ 645.73M 28.25M
Adamas Pharmaceuticals ADMS:US 115.66M 42.45M
Aerie Pharmaceuticals AERI:US $ 289.02M 4.56M
Aptinyx Inc APTX:US $ 133.78M 18.63M
Flexion Therapeutics FLXN:US $ 184.12M 20.5M
GlaxoSmithKline GSK:LN 17.57B 958M
Glaxosmithkline GSK:US $ 17566M 958M
Gw Pharmaceuticals GWPH:US $ 718.73M 10.8M
Heron Therapeutics HRTX:US $ 366.83M 94.54M
Intra Cellular Therapies ITCI:US $ 601.3M 47.8M
Marinus Pharmaceuticals MRNS:US $ 120.92M 8.87M
Neurocrine Biosciences NBIX:US $ 1110.1M 24.7M
Novartis NOVN:VX 23.81B 1.61B
Omeros OMER:US $ 112.4M 20.08M
Prothena PRTA:US 409.47M 57.17M
Revance Therapeutics RVNC:US $ 354.6M 51.82M
Teva Pharmaceutical TEVA:IT 12.82B 421M
Zogenix ZGNX:US $ 416.39M 38.34M